Trial Profile
Phase II study to evaluate efficacy and safety of sunitinib therapy in patients with metastatic renal clear cell carcinoma who have progressed to first-line immunotherapy treatment (INMUNOSUN Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2020
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms INMUNOSUN
- 06 Oct 2020 Status changed from recruiting to completed.
- 31 May 2020 Results (n=20) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 28 Feb 2020 Planned End Date changed from 31 May 2020 to 1 Mar 2021.